

NOVEL DELETIONS AND UNUSUAL GENETIC MECHANISMS UNDERLYING ALPHA-THALASSEMIA

Ferrão J¹, Silva M¹, Gonçalves L¹, Gomes S¹, Coelho A¹, Miranda A², Seuanes F², Batalha-Reis A³, Valtonen-André C⁴, Sonesson A⁴, Pina F⁵, Forjaz-Lacerda J⁶, Maia R⁷, Kjollerström P⁷, Lavinha J^{1,8}, Gonçalves J^{1,9}, Faustino P^{1,10}

¹Departamento de Genética Humana, Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA), Lisboa; ²Departamento de Promoção da Saúde e Doenças não Transmissíveis, INSA, Lisboa; ³Serviço de Patologia Clínica, Hospital São Francisco Xavier, Centro Hospitalar Lisboa Ocidental, Lisboa; ⁴Lund University, Lund, Sweden; ⁵Serviço de Hemato-Oncologia, Hospital do Espírito Santo, Évora; ⁶British Hospital, Lisboa; ⁷Unidade de Hematologia, Hospital de D. Estefânia; Centro Hospitalar Lisboa Central, Lisboa; ⁸BioISI, Faculdade de Ciências da Universidade de Lisboa, Lisboa; ⁹ToxOmics, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa; ¹⁰ISAMB, Faculdade de Medicina, Universidade de Lisboa, Lisboa.

INTRODUCTION

Hemoglobin (Hb) is a protein responsible for oxygen transportation from lungs to the entire body. It is composed by four globular subunits - the globins - each with a central core containing a heme molecule. Globins are encoded by the α - and β -globin gene clusters located at 16p13.3 and 11p15.5, respectively¹. The pattern of globin genes expression during development is precisely controlled by the interaction of *cis*-regulatory genomic regions (located in close proximity to and far from genes) with *trans*-activating/silencing factors within permissive chromatin domains. In fact, approximately 25-65 kb upstream of the α -globin genes there are four multispecies conserved sequences (MCS-R1 to R4) which are critical for the expression regulation of the downstream globin genes^{1,2}.

The main objectives of this work were to characterize the molecular lesions underlying **eleven unusual cases of α -thalassemia or Hb H disease (Table I)**, and to understand their origin and functional consequences.

METHODS

Multiplex Ligation-dependent Probe Amplification (MLPA) is appropriated to investigate large chromosomal regions, searching for changes in the copy number of a certain DNA sequence. It consists of two adjacent oligonucleotides hybridization followed by their ligation and amplification by PCR. Only the hybridized and ligated oligonucleotides (MLPA probe) will amplify according to the amount of target sequence present in the genome. Each MLPA reaction allows the amplification of several probes with only one set of primers. Capillary electrophoresis is used to separate MLPA amplification products based on their size. In this study, each sample was tested in duplicate and compared to the average result of three normal controls in the same assay. The peak areas were used in the subsequent graphic analysis.

In order to study genomic regions not contemplated by commercial MLPA probes (SALSA MLPA P140B HBA), we designed **synthetic probes** according to MCR-Holland instructions. Whenever possible **gap-PCR** and automatic **Sanger sequencing** were used to confirm MLPA results and map deletion breakpoints.

RESULTS

We have found **seven different large deletions in the alpha-globin gene cluster** (ranging from \approx 3.3 to 323 kb), four of them not previously described (Table I, Figure 1).

➤ The four largest deletions removed all the α -globin genes (Del. 1, 2, 3, and 4), whereas the other three deletions (Del. 5, 6, and 7) removed one or more of the distal regulatory elements keeping the globin genes structurally intact.

➤ In one case (Del.7), only the MCS-R2 (also known as HS-40) was removed and replaced by a 39nt DNA fragment (Figure 2) possibly resulting from a complex rearrangement that introduces new pieces of DNA (probably from Chrs. 3 and 7) bridging the two deletion breakpoints. This rearrangement has been previously described by our group in another family³.

➤ In the remaining case, no deletion (No Del.) was found and the patient revealed to be a very unusual case of acquired alpha-thalassemia-myelodysplastic syndrome (ATMDS). We will further investigate the *ATRX* gene for somatic mutations⁴.

Table I - Demographic, hematological and biochemical data of the patients

Patient	Gender/ Age (yrs)	Geographic origin	Hematological and biochemical parameters					α -globin cluster deletion
			RBC ($10^{12}/L$)	Hb (g/dL)	MCV (fL)	MCH (pg)	HbA ₂ (%)	
1	F/17	Portuguese	5.47	10.4	63.2	19	2.4	Del.1
2	F/39	Portuguese	5.41	11.5	68.0	21.3	-	Del.1
3	F/36	Portuguese	5.02	11.4	71.9	22.8	2.3	Del.2 [#]
4*	F/?	Portuguese	4.96	11.0	70.9	22.1	2.5	Del.2 [#]
5	F/11	Sweden	-	11.0	65.0	20.0	-	Del.3 [#]
6	F/21	Portuguese	5.19	11.4	69.3	22	2.3	Del.4 [#]
7	F/40	Portuguese	5.2	10.5	65	20.1	2.2	Del.5 [#]
8*	M/10	Portuguese	5.31	10.8	64.7	20.3	2.5	Del.5 [#]
9	F/31	Portuguese	5.03	10.7	68.2	21.4	2.3	Del.6
10	M/?	Portuguese	5.41	11.9	67.4	21.9	-	Del.7
11	F/61	Portuguese	4.19	7.7	71.6	18.3	1.9	No Del.

RBC: red blood cell count; Hb: hemoglobin; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin;
Patient 4* is the sister of patient 3; Patient 8* is the son of patient 7;
[#] novel deletions.





Figure 1. (A) Schematic representation of 4 Mb from the sub-telomeric region of chr16p, containing the α -globin gene cluster. MLPA probe hybridization sites are indicated by green and orange arrows referring to commercial and synthetic probes, respectively. Each probe is numbered according to their sequential order of chromosomal hybridization. Probe density might not allow individual numbering and therefore probe intervals are shown. Thin lines indicate the region of uncertainty for deletion breakpoints. The oval shape represents the telomere. MCS-Rs are represented by vertical dark grey bars in or nearby *NPRL3* gene. (B) MLPA probe ratios (y-axis) were determined by comparison of their signal quantification in the studied individuals and in normal controls. MLPA probe numbers are displayed in the x-axis. Deleted sequences present a probe amplification ratio around 0.5 when in heterozygosity and around zero when the target sequence is deleted in both alleles (exceptions include probes nos. 33 and 36 which hybridize in both *HBA2* and *HBA1* and therefore, ratio can vary by 0.25 fold). Probe no. 37 is amplified only in the presence of Hb Constant Spring (\blacktriangle). *Indicates breakpoint location of deletion 4 in the α -globin gene cluster detailed region.



Alpha-thalassemia-myelodysplastic syndrome (ATMDS)

Patient 11 presents an **acquired microcytic, hypochromic anemia** and normal iron status. Two years earlier she had normal hemoglobin and hematimetric parameters. There is no family history of hematologic disorder and iron metabolism deficiency. Results from isoelectric focusing suggested the presence of **Hb H**. It was confirmed and quantitated (29.7%) by capillary hemoglobin electrophoresis. Supravital staining of the patient's peripheral blood demonstrated approximately **50% of Hb H-containing cells**. Analysis of the α -globin loci by MLPA denoted no deletion. The Sanger sequencing of *HBA1* and *HBA2* did not reveal pathogenic gene variants.

CONCLUSION

It is important to detect individuals with this type of uncommon deletions as there is a 25% risk of having a child with Hb Bart's hydrops fetalis or Hb H disease if their partner is a carrier of an α^0 -thal or α^+ -thal allele, respectively. Moreover, further investigation is currently being developed on one of these natural mutants which is bringing new insights into the long-range regulation mechanism of the globin gene expression and to the pathophysiology of the α -thalassemia.

REFERENCES

- Harteveld CL & Higgs DR. α -thalassaemia. *Orphanet Journal of Rare Diseases* 2010, 5:13
- Higgs DR. The molecular basis of α -thalassaemia. *Cold Spring Harbor Perspect Med* 2013, 3:a011718
- Coelho A, Picanço I, Seuanes F, Seixas MT, Faustino P. Novel large deletions in the human α -globin gene cluster: Clarifying the HS-40 long-range regulatory role in the native chromosome environment. *Blood Cells, Molecules, and Diseases* 2010, 45: 147-153
- Davids MS & Steensma DP. The molecular pathogenesis of myelodysplastic syndromes. *Cancer Biology & Therapy* 2010, 10: 309-319